Results of a retrospective multicenter study have confirmed that adalimumab is safe and efficacious for treatment of moderate-to-severe psoriasis among previously treated patients and those naive to biologic treatments.
Susana Armesto, MD, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain, and colleagues enrolled in the study of 100 patients with moderate-to-severe psoriasis who were treated uninterruptedly with adalimumab (Humira) between 6 and 36 months; median follow-up was 18 months (interquartile range 10–24 months). Ninety percent of patients had plaque-type psoriasis.
Of the 52 men and 48 women in the study, 53 patients were previously treated with biologics and 47 patients were treated with non-biologics. The mean baseline Psoriasis Area and Severity Index (PASI) score was 15.9 in the previously treated group.
Sixteen weeks into the treatment regimen, 94% of the patients presented PASI 75 response, 76% PASI 90, and 39% were in complete remission (PASI 100).
These results were similar in both study groups. During the final follow-up, approximately 37% in all groups were in complete remission.
At the end of the study, 31 patients in the non-biologic naive group and 43 patients in the biologic-naive group (P<0.001) continued treatment with adalimumab.